Silver Book Fact

Use of shingles vaccines significantly reduced disease burden

Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.

Oxman, M.N., M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, et al; for the Shingles Prevention Study Group. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. NEJM. 2005; 352(22): 2271-84. http://www.nejm.org/doi/full/10.1056/NEJMoa051016

Reference

Title
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
NEJM
Publication Date
2005
Authors
Oxman, M.N., M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, et al; for the Shingles Prevention Study Group
Volume & Issue
Volume 352, Issue 22
Pages
2271-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
  • Mortality from vaccine-preventable diseases
    Vaccine-preventable diseases or their complications account for 50,000 to 90,000 adult deaths in the U.S. each year.  
  • Potential cost effectiveness of shingles vaccines
    The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…  
  • Savings from flu vaccine
    Vaccination for influenza resulted in an average annual cost savings of $13.66 per healthy working adult vaccinated.  
  • Use of shingles vaccines significantly reduced disease burden
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.